(Boursier.com) — Biosenic a company specializing in clinical trials in serious autoimmune and inflammatory diseases and cell therapy, today announces the receipt of transparency notifications from François Rieger, Véronique Pomi, FA Dièse 3 SAS and Capital Grand Est SAS.
The transparency notification indicates that François Rieger’s shareholder positions have crossed the passive participation threshold of 20% following the issuance of new BioSenic shares on August 10, 2023.
©2023 Boursier.com